| Gene symbol | LMP2 | Synonyms | None | Type of gene | protein-coding | |
| Chromosome | - | Map location | NC_007605.1 | dbXrefs | Entrez:17494212 - | |
| Description | EBNA3A nuclear protein | |||||
| GTO ID | GTC2096 |
| Trial ID | NCT03925896 |
| Disease | Nasopharyngeal Disease |
| Altered gene | EBV-LMP2 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | LMP2 TCR-T cells |
| HLA | HLA-A*02|HLA-A*11|HLA-A*24 |
| Phase | Phase1 |
| Recruitment status | Unknown |
| Title | LMP2 Antigen-specific High-affinity T Cell Receptor (TCR)-Transduced Autologous T-cell Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma, an Open-label, Single-center, Phase I Clinical Trial |
| Year | 2019 |
| Country | China |
| Company sponsor | Sun Yat-sen University |
| Other ID(s) | B2019-021 |
| Cohort 1 | |||||||||||
|
|||||||||||